Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia

The Journal of Clinical Psychiatry
Stanley N CaroffCATIE Investigators

Abstract

We compared the response to antipsychotic treatment between patients with and without tardive dyskinesia (TD) and examined the course of TD. This analysis compared 200 patients with DSM-IV-defined schizophrenia and TD and 997 patients without TD, all of whom were randomly assigned to receive one of 4 second-generation antipsychotics. The primary clinical outcome measure was time to all-cause treatment discontinuation, and the primary measure for evaluating the course of TD was change from baseline in Abnormal Involuntary Movement Scale (AIMS) score. Kaplan-Meier survival analysis and Cox proportional hazards regression models were used to compare treatment discontinuation between groups. Changes in Positive and Negative Syndrome Scale (PANSS) and neurocognitive scores were compared using mixed models and analysis of variance. Treatment differences between drugs in AIMS scores and all-cause discontinuation were examined for those with TD at baseline. Percentages of patients meeting criteria for TD postbaseline or showing changes in AIMS scores were evaluated with χ(2) tests. Data were collected from January 2001 to December 2004. Time to treatment discontinuation for any cause was not significantly different between the TD and n...Continue Reading

References

Jan 31, 1978·Psychopharmacology·G M SimpsonR K Shrivastava
Apr 1, 1991·The British Journal of Psychiatry : the Journal of Mental Science·Jeffrey LiebermanJohn M Kane
Jun 1, 1991·The British Journal of Psychiatry : the Journal of Mental Science·W M GlazerJ T Doucette
May 1, 1989·The British Journal of Psychiatry : the Journal of Mental Science·T R Barnes
Jan 1, 1985·Schizophrenia Bulletin·T J Crow
Aug 1, 1988·Journal of Clinical Psychopharmacology·G ChouinardP Mercier
Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Jan 1, 1970·Acta Psychiatrica Scandinavica. Supplementum·G M Simpson, J W Angus
Apr 1, 1982·Archives of General Psychiatry·N R Schooler, John M Kane
Jul 1, 1982·Archives of General Psychiatry·Dilip V Jeste, R J Wyatt
Oct 1, 1983·The British Journal of Psychiatry : the Journal of Mental Science·E T Barron, Robin G McCreadie
Oct 1, 1994·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Jeffrey LiebermanJohn M Kane
May 1, 1993·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·R CavallaroE Smeraldi
Feb 1, 1996·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·C M BeasleyS Hamilton
Oct 15, 1998·The Journal of Clinical Psychiatry·S AhmedN R Schooler
Jun 29, 2002·The Journal of Clinical Psychiatry·Steven R HirschRory O'Connor
Nov 2, 2002·The British Journal of Psychiatry : the Journal of Mental Science·Jennifer HallidayRobin G McCreadie
Dec 4, 2003·JAMA : the Journal of the American Medical Association·Robert A RosenheckDepartment of Veterans Affairs Cooperative Study Group on the Cost-Effectiveness of Olanzapine
May 28, 2004·The Journal of Clinical Psychiatry·Robin EmsleyPiet P Oosthuizen
Sep 21, 2005·The New England Journal of Medicine·Jeffrey LiebermanClinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Dec 1, 2005·International Clinical Psychopharmacology·Jonas EberhardSten Levander
Mar 15, 2006·Movement Disorders : Official Journal of the Movement Disorder Society·Daniel Tarsy, Ross J Baldessarini
Apr 28, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Richard S E KeefeJeffrey Lieberman
Jun 6, 2007·Archives of General Psychiatry·Richard S E KeefeNeurocognitive Working Group
Sep 4, 2007·The British Journal of Psychiatry : the Journal of Mental Science·Robert A Rosenheck
Dec 7, 2007·Schizophrenia Research·Jiri ModestinPuspa Agarwalla
Oct 2, 2008·The British Journal of Psychiatry : the Journal of Mental Science·Del D MillerClinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Jan 15, 2009·Journal of Clinical Psychopharmacology·Siow-Ann ChongDavid Machin
Feb 5, 2009·The Journal of Clinical Psychiatry·Haya Ascher-SvanumMauricio Tohen
Jul 3, 2009·The American Journal of Psychiatry·Sophia VinogradovBruce G Pollock

Citations

Oct 3, 2013·Journal of Psychiatry & Neuroscience : JPN·Michael CoesmansJosef N van der Geest
Dec 24, 2013·Journal of Psychiatry & Neuroscience : JPN·Gary Remington, Margaret Hahn
Dec 22, 2010·Neurologic Clinics·Stanley N CaroffE Cabrina Campbell
May 23, 2014·Expert Opinion on Pharmacotherapy·Leora L Borek, Joseph H Friedman
Dec 12, 2012·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Alkomiet HasanWFSBP Task force on Treatment Guidelines for Schizophrenia
Aug 16, 2016·The Psychiatric Clinics of North America·Stanley N Caroff, E Cabrina Campbell
Feb 7, 2018·The Cochrane Database of Systematic Reviews·Hanna BergmanKarla Soares-Weiser
Oct 3, 2017·Journal of Comparative Effectiveness Research·Stanley N CaroffCharles Yonan
Feb 1, 2019·Neurodegenerative Disease Management·Nicki Niemann, Joohi Jimenez-Shahed
Aug 16, 2017·Health Technology Assessment : HTA·Hanna BergmanClive E Adams
Dec 14, 2019·Journal of Clinical Psychopharmacology·Stanley N CaroffE Cabrina Campbell
Feb 6, 2019·Current Opinion in Psychiatry·Christian G Widschwendter, Alex Hofer
May 19, 2020·CNS Spectrums·Jean-Pierre LindenmayerChristopher F O'Brien
Jul 21, 2017·Expert Review of Neurotherapeutics·Stanley N CaroffBenjamin Carroll
Jul 13, 2017·Expert Opinion on Pharmacotherapy·Lauren C Seeberger, Robert A Hauser
Oct 13, 2009·The Cochrane Database of Systematic Reviews·Katja KomossaStefan Leucht
Aug 30, 2019·Journal of Comparative Effectiveness Research·Saurabh AggarwalChuck Yonan
Oct 31, 2020·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Stanley N Caroff
Dec 25, 2018·Journal of Affective Disorders·Roger S McIntyreJoshua Burke
Nov 11, 2019·The Nursing Clinics of North America·Sattaria DilksJessica Johnson

Related Concepts

Ziprasidone hydrochloride, monohydrate
Quetiapine
Benzodiazepines
Dibenzothiazepines
Etat Marbre
Trilafon
Piperazines
Factor Construct Rating Scales (Fcrs)
Schizophrenia
Severity of Illness Index

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here